Nrf2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that activates transcription of a battery of cytoprotective genes by binding to the ARE (antioxidant response element). Nrf2 is repressed by the cysteine-rich Keap1 (kelch-like ECH-associated protein 1) protein, which targets Nrf2 for ubiquitination and subsequent degradation by a Cul3 (cullin 3)-mediated ubiquitination complex. We find that modification of Cys151 of human Keap1, by mutation to a tryptophan, relieves the repression by Keap1 and allows activation of the ARE by Nrf2. The Keap1 C151W substitution has a decreased affinity for Cul3, and can no longer serve to target Nrf2 for ubiquitination, though it retains its affinity for Nrf2. A series of 12 mutant Keap1 proteins, each containing a different residue at position 151, was constructed to explore the chemistry required for this effect. The series reveals that the extent to which Keap1 loses the ability to target Nrf2 for degradation, and hence the ability to repress ARE activation, correlates well with the partial molar volume of the residue. Other physico-chemical properties do not appear to contribute significantly to the effect. Based on this finding, a structural model is proposed whereby large residues at position 151 cause steric clashes that lead to alteration of the Keap1–Cul3 interaction. This model has significant implications for how electrophiles which modify Cys151, disrupt the repressive function of Keap1.
Skip Nav Destination
Follow us on Twitter @Biochem_Journal
Article navigation
August 2009
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Research Article|
July 29 2009
Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1 Available to Purchase
Aimee L. Eggler;
Aimee L. Eggler
1
*Center for Pharmaceutical Biotechnology and the Department of Medicinal Chemistry and Pharmacognosy, University of Illinois, Chicago, IL 60607, U.S.A.
1Correspondence may be addressed to either of these authors (emails [email protected] or [email protected]).
Search for other works by this author on:
Evan Small;
Evan Small
*Center for Pharmaceutical Biotechnology and the Department of Medicinal Chemistry and Pharmacognosy, University of Illinois, Chicago, IL 60607, U.S.A.
Search for other works by this author on:
Mark Hannink;
Mark Hannink
†Department of Biochemistry, University of Missouri, Columbia, MO 65212, U.S.A.
Search for other works by this author on:
Andrew D. Mesecar
Andrew D. Mesecar
1
*Center for Pharmaceutical Biotechnology and the Department of Medicinal Chemistry and Pharmacognosy, University of Illinois, Chicago, IL 60607, U.S.A.
1Correspondence may be addressed to either of these authors (emails [email protected] or [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
March 27 2009
Revision Received:
May 21 2009
Accepted:
June 02 2009
Accepted Manuscript online:
June 02 2009
Online ISSN: 1470-8728
Print ISSN: 0264-6021
© The Authors Journal compilation © 2009 Biochemical Society
2009
Biochem J (2009) 422 (1): 171–180.
Article history
Received:
March 27 2009
Revision Received:
May 21 2009
Accepted:
June 02 2009
Accepted Manuscript online:
June 02 2009
Citation
Aimee L. Eggler, Evan Small, Mark Hannink, Andrew D. Mesecar; Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1. Biochem J 15 August 2009; 422 (1): 171–180. doi: https://doi.org/10.1042/BJ20090471
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Follow us on Twitter @Biochem_Journal
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() View past webinars > |